Skip to content
OpenCapital
Get started
Income StatementBalance SheetCash FlowSegments
Cardinal Health logo

Cardinal Health Business Segments

Business, geographic, and product segment breakdowns

Cardinal Health generates $250.74B in annual revenue across 3 key segments: Cost of product sold ($12.8B), Other Segments ($6.7B), and Pharmaceutical and Specialty Solutions ($231.36B). The company-wide operating margin is 0.922%. Based on the Q1 2026 filing.

Cost of product sold (TTM)$12.8BOther Segments (TTM)$6.7BPharmaceutical and Specialty Solutions (TTM)$231.36B
Latest FilingQ1 2026
Report Date2026-04-30
Market Cap$51.8B
P/E Ratio33.31
ROE37.39%

Products & Services

MetricQ2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Distribution, selling, general, and administrative expenses$227.3M$227.3M$227.3M———

Geographic

PP&E (Net)

SegmentQ2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
UNITED STATES——$2.4B$2.4B$2.4B$2.5B
Non-US——$436M$435M$432M$434M

Revenue

SegmentQ2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
UNITED STATES$54.9B$54.5B$59.7B$63.6B$65.2B$60.5B
Non-US$428M$399M$434M$419M$435M$423M

Business Segments

Cost of products sold

SegmentQ2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Pharmaceutical and Specialty Solutions$49.8B$49.2B$54.2B$57.9B$59.2B$54.6B
Cost of product sold$2.6B$2.6B$2.6B$2.6B$2.7B$2.6B
Other Segments$969M$975M$1.2B$1.2B$1.3B$1.3B

Costs and Expenses

SegmentQ2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Pharmaceutical and Specialty Solutions$50.3B$49.8B$54.8B$58.5B$60B$55.3B
Cost of product sold$3.1B$3.1B$3.1B$3.1B$3.2B$3.1B
Other Segments$1.2B$1.2B$1.4B$1.5B$1.5B$1.5B

D&A

SegmentQ2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Pharmaceutical and Specialty Solutions$46M$44M$68M$61M$64M$70M
Cost of product sold$60M$56M$47M$55M$55M$54M
Other Segments$40M$31M$0$29M$30M$26M

Distribution, selling, general and administrative expenses

SegmentQ2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Pharmaceutical and Specialty Solutions$568M$604M$664M$681M$739M$732M
Cost of product sold$512M$487M$521M$505M$502M$518M
Other Segments$196M$195M$254M$254M$254M$259M

Goodwill

SegmentQ2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Pharmaceutical and Specialty Solutions$4.3B$7.7B$7.9B$8B$9.9B$9.7B
Other Segments$1.2B$1.2B$1.7B$1.7B$1.7B$1.7B
Cost of product sold$0$0$0$0$0$0

Goodwill, Acquired During Period

SegmentQ2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Other Segments$0$0$578M-$3M$3M-$1M
Cost of product sold$0$0$0$0$0$0
Pharmaceutical and Specialty Solutions$763M$3.4B$208M$21M$1.9B—

Goodwill, Impairment Loss

SegmentQ2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Pharmaceutical and Specialty Solutions—————$184M

Revenue

SegmentQ2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Pharmaceutical and Specialty Solutions$50.8B$50.4B$55.4B$59.2B$60.7B$56.1B
Cost of product sold$3.2B$3.2B$3.2B$3.2B$3.3B$3.1B
Other Segments$1.3B$1.3B$1.6B$1.6B$1.7B$1.7B

Segment Reporting, Long-Lived Asset, Expenditure for Addition

SegmentQ2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Pharmaceutical and Specialty Solutions$12M$33M$62M$32M$23M$37M
Cost of product sold$21M$28M$61M$19M$23M$32M
Other Segments$22M$18M$36M$15M$23M$25M

Total Assets

SegmentQ2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Pharmaceutical and Specialty Solutions$32.1B$35.7B$37.3B$38.7B$43.4B$41B
Cost of product sold$7.1B$7.2B$6.9B$7.1B$7B$6.9B
Other Segments$2.7B$2.7B$4B$4B$4.1B$4.1B

Total operating earnings

SegmentQ2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Pharmaceutical and Specialty Solutions$531M$662M$535M$667M$687M$784M
Other Segments$118M$134M$160M$166M$179M$179M
Cost of product sold$18M$39M$70M$46M$37M$25M

Accumulated goodwill impairment loss

SegmentQ2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Other Operating Segment——$829M———

Number of operating segments

SegmentQ2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Other Segments———3.00——

Percent of Gross Trade Receivables

SegmentQ2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Pharmaceutical and Specialty Solutions——26.0%———